Fig. 1 · Structure
Documents & Downloads
Fosalvudine tidoxil
NRTI
Fosalvudine tidoxil is an orally active nucleoside reverse transcriptase inhibitor (NRTI) designed for the treatment of HIV-1 infection. As a prodrug of Alovudine, it exhibits reduced toxicity compared to its progenitor, making it a valuable tool for research applications related to antiretroviral therapy and HIV pathology. Its effectiveness as an NRTI provides critical insights into the mechanisms of viral replication and potential therapeutic strategies against HIV-1.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 763903-67-9 |
| Applications | NRTI |
| Formula | C35H64FN2O8PS |
| Molecular Weight | 722.93 |
| SMILES | O=P(OC[C@H]1O[C@@H](N(C(N2)=O)C=C(C)C2=O)C[C@@H]1F)(OCC(OCCCCCCCCCC)CSCCCCCCCCCCCC)O |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.